bioAffinity Technologies, Inc. (BIAF): Total Assets

Annual figures by period end, from SEC filings.

$10.96M
As of 2025-12-31
$7.62M
As of 2026-06-30
-3.5%
3-year compound annual growth
$12.18M2021-12-31: $1.45M2022-12-31: $12.18M2023-12-31: $8.22M2024-12-31: $6.51M2025-12-31: $10.96M$10.96M
2021-12-31 Total Assets (USD) 2025-12-31
Period endedTotal AssetsChange YoYSource filing
2025-12-31$10.96M+68.3%2026-03-16, Balance as of period end
2024-12-31$6.51M-20.8%2026-03-16, Balance as of period end
2023-12-31$8.22M-32.5%2025-03-31, Balance as of period end
2022-12-31$12.18M+738.2%2024-04-01, Balance as of period end
2021-12-31$1.45Mn/a2023-03-31, Balance as of period end

Total Assets at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal AssetsChange YoY
bioAffinity Technologies, Inc. (BIAF)2025-12-31$10.96M+68.3%
Absci Corp (ABSI)2025-12-31$216.30M+1.3%
Foxo Technologies Inc. (FOXO)2025-12-31$44.58M+6.9%
OmniAb, Inc. (OABI)2025-12-31$300.91M-7.6%
iSpecimen Inc. (ISPC)2025-12-31$9.53M+1.9%
OneMedNet Corp (ONMD)2025-12-31$2.15M-42.3%
MaxCyte, Inc. (MXCT)2025-12-31$202.51M-15.4%
Cannabis Bioscience International Holdings, Inc. (CBIH)2025-05-31$31.9K-44.2%
NRC Health (NRC)2025-12-31$134.88M+1.8%

Compare BIAF, ABSI, FOXO, OABI side by side · Screen every company in Services-Commercial Physical & Biological Research ↗